GO:1903542 negative regulation of exosomal secretion: Regulation, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1903542 describes any process that stops, prevents, or reduces the frequency, rate, or extent of exosomal secretion.
• Exosomal secretion is a multistep process involving multivesicular body (MVB) biogenesis, cargo sorting, and fusion with the plasma membrane; negative regulation can occur at any of these steps.
• Key regulatory proteins include Rab GTPases, ESCRT components, and lipids such as phosphatidic acid and phosphatidylserine.
• Dysregulation of exosomal secretion is implicated in cancer progression, immune evasion, and neurodegeneration.
• Experimental models for studying negative regulation include CRISPR knockout of regulatory genes, point mutations, and overexpression of inhibitory proteins.
• EDITGENE provides CRISPR services to dissect the molecular players that negatively regulate exosomal secretion.
Description
Exosomes are small extracellular vesicles (30–150 nm) of endosomal origin that mediate intercellular communication by transferring proteins, lipids, and nucleic acids. Their secretion is a tightly regulated process that can be modulated at multiple levels, including multivesicular body (MVB) formation, cargo sorting, and fusion with the plasma membrane. The Gene Ontology (GO) term GO:1903542, negative regulation of exosomal secretion, captures any process that stops, prevents, or reduces the frequency, rate, or extent of exosomal secretion. Understanding this process is critical because exosomes are implicated in diverse physiological and pathological contexts, from cancer progression to neurodegeneration [5,7]. For researchers, identifying the molecular brakes on exosomal secretion can reveal therapeutic targets to modulate intercellular communication. This article synthesizes current knowledge on the mechanisms, key genes, and experimental approaches for studying negative regulation of exosomal secretion, based on published literature.
negative regulation of exosomal secretion At A Glance
| GO ID | GO:1903542 |
|---|---|
| GO term | negative regulation of exosomal secretion |
| Ontology | biological_process |
| Synonym | inhibition of exosomal secretion; downregulation of exosomal secretory pathway; negative regulation of extracellular vesicular exosome secretion |
| Major function | Inhibits the release of exosomes by interfering with MVB formation, cargo sorting, or fusion with the plasma membrane. |
| Related processes | Multivesicular body organization, endosomal transport, regulation of secretion |
| Disease relevance | Cancer, neurodegenerative disorders, immune evasion |
| Research methods | CRISPR knockout, RNA interference, live-cell imaging, proteomics |
What Is GO:1903542?
GO:1903542 (negative regulation of exosomal secretion) is a biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of exosomal secretion. It encompasses mechanisms that inhibit the release of exosomes, which are extracellular vesicles formed within multivesicular bodies (MVBs) and released upon fusion of MVBs with the plasma membrane. This regulation can occur at various steps, including MVB biogenesis, cargo selection, and membrane fusion.
Why Is negative regulation of exosomal secretion Important in Cell Biology?
Negative regulation of exosomal secretion is crucial for maintaining cellular homeostasis and preventing pathological intercellular communication. Exosomes can transfer oncogenic proteins, miRNAs, and immune-modulatory molecules, thereby promoting tumor progression and immune evasion. Conversely, excessive or aberrant exosome secretion contributes to neurodegeneration by spreading misfolded proteins. Understanding the negative regulators of exosomal secretion provides insights into basic cell biology and offers potential therapeutic targets for diseases where exosome-mediated communication is dysregulated.
• Controls the spread of oncogenic signals between cancer cells and the tumor microenvironment.
• Modulates immune responses by regulating exosomal PD-1 secretion and myeloid-derived suppressor cell activity.
• Prevents pathological protein aggregation in neurodegenerative diseases such as Alzheimer's and Parkinson's [2,7].
• Influences tissue repair and regeneration through exosome-mediated paracrine signaling.
• Affects viral spread, as exosomes can package viral components.
• Regulates stem cell niche communication and differentiation.
• Provides targets for modulating drug resistance in cancer.
• Impacts metabolic disorders by altering inter-organ communication.
• Serves as a quality control mechanism for protein and RNA homeostasis.
• Offers opportunities for engineering exosomes for drug delivery.
What Happens During negative regulation of exosomal secretion?
Inhibition of Multivesicular Body (MVB) Biogenesis
In simple terms: The cell makes fewer or smaller MVBs, the compartments that become exosomes.
Negative regulation of exosomal secretion can occur by reducing the number or size of MVBs. This involves inhibition of ESCRT (Endosomal Sorting Complex Required for Transport) components or lipids such as phosphatidic acid. For example, depletion of ESCRT-III subunits decreases exosome release. Additionally, proteins like Rab7 and Rab27b regulate MVB docking and fusion, and their inhibition reduces exosome secretion.
Alteration of Cargo Sorting
In simple terms: The cell changes which molecules get packaged into exosomes, affecting their release.
Cargo sorting into exosomes is mediated by ESCRT-dependent and -independent mechanisms. Negative regulation can involve preventing the incorporation of specific miRNAs or proteins into exosomes. For instance, enterotoxigenic Bacteroides fragilis inhibits exosome-packaged miR-149-3p, thereby reducing exosome-mediated anti-inflammatory effects. Similarly, miR-144-3p can promote ferroptosis and inhibit exosome secretion in osteosarcoma.
Inhibition of MVB Fusion with Plasma Membrane
In simple terms: The MVBs are prevented from fusing with the cell surface, so exosomes are not released.
The final step of exosomal secretion is the fusion of MVBs with the plasma membrane, which requires SNARE proteins and Rab GTPases. Negative regulation can occur by downregulating these fusion machinery components. For example, knockdown of Rab27a or Rab27b reduces exosome release. Additionally, proteins such as VAMP7 and syntaxin-1 are involved in fusion, and their inhibition blocks secretion.
Regulation by microRNAs and Signaling Pathways
In simple terms: Small RNAs and signaling molecules can turn down exosome production.
MicroRNAs can negatively regulate exosomal secretion by targeting mRNAs encoding proteins involved in MVB biogenesis or fusion. For instance, miR-20b-3p in plasma exosomes improves peripheral neuropathy via Stat3 signaling. Similarly, exosome-mediated miR-144-3p promotes ferroptosis and inhibits osteosarcoma progression. Signaling pathways such as PINK1/Parkin are activated by exosomes to protect against oxidative stress.
Role of Exosome-like Nanovesicles in Therapy
In simple terms: Plant-derived nanovesicles can deliver miRNAs and inhibit exosome secretion in cancer.
Brucea javanica-derived exosome-like nanovesicles deliver miRNAs for cancer therapy, demonstrating that exogenous vesicles can modulate exosomal secretion pathways. Chaihu-Shugan-San alleviates post-stroke depression via exosome-mediated neuroprotection, indicating that pharmacological interventions can affect exosome release.
Key Genes Involved in GO:1903542 negative regulation of exosomal secretion
The following genes and proteins are key players in the negative regulation of exosomal secretion, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| Rab27a | Regulates MVB docking and fusion with plasma membrane | Knockdown reduces exosome release; target for cancer therapy |
| Rab27b | Regulates MVB docking and fusion | Inhibition decreases exosome secretion |
| Rab7 | Late endosomal trafficking | Modulates MVB maturation and exosome release |
| ESCRT-III | MVB biogenesis and cargo sorting | Depletion reduces exosome secretion |
| miR-144-3p | Promotes ferroptosis and inhibits osteosarcoma progression | Exosome-mediated delivery affects tumor growth |
| miR-149-3p | Anti-inflammatory miRNA packaged in exosomes | Inhibited by enterotoxigenic Bacteroides fragilis |
| miR-20b-3p | Improves peripheral neuropathy via Stat3 | Plasma exosomes as therapeutic agents |
| PINK1 | Mitophagy and oxidative stress protection | Activated by neural stem cell exosomes |
| Parkin | Mitophagy and oxidative stress protection | Activated by neural stem cell exosomes |
| BDNF | Neurotrophic factor | Exosomes from BMSCs alleviate cognitive decline |
| PD-1 | Immune checkpoint protein | Secreted in exosomes to enhance MDSC activity |
| Stat3 | Signal transducer and transcription factor | Mediates miR-20b-3p effects in neuropathy |
| ZEB1 | Transcriptional repressor | Regulated by miR-144-3p in osteosarcoma |
| VAMP7 | SNARE protein involved in MVB fusion | Inhibition blocks exosome release |
| Syntaxin-1 | SNARE protein involved in MVB fusion | Inhibition blocks exosome release |
| Alix | ESCRT accessory protein | Involved in MVB biogenesis and exosome secretion |
| TSG101 | ESCRT-I component | Knockdown reduces exosome secretion |
| CD63 | Tetraspanin marker of exosomes | Used as a marker for exosome quantification |
How Is negative regulation of exosomal secretion Regulated?
Negative regulation of exosomal secretion is controlled by a complex network of signaling pathways and molecular switches. Key regulators include Rab GTPases (e.g., Rab27a/b), ESCRT components, and lipids such as phosphatidic acid. MicroRNAs can fine-tune exosome release by targeting mRNAs of these proteins [1,4]. Additionally, extracellular stimuli such as inflammatory cytokines or stress conditions can modulate exosome secretion. For instance, enterotoxigenic Bacteroides fragilis inhibits exosome-packaged miR-149-3p, thereby altering exosome-mediated intercellular communication. The PINK1/Parkin pathway, activated by exosomes, protects against oxidative stress and may feedback to regulate exosome release. These regulatory mechanisms ensure that exosome secretion is tightly controlled in response to cellular needs.
negative regulation of exosomal secretion and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| miR-144-3p | Osteosarcoma | Knockout of miR-144-3p in osteosarcoma cell lines; exosome secretion assays |
| PD-1 | Prostate cancer immune evasion | Overexpression of PD-1 in prostate cancer cells; exosome isolation and MDSC activity assays |
| BDNF | Alzheimer's disease | BMSC-derived exosomes in AD mouse models; cognitive tests |
| PINK1/Parkin | Ischemic stroke | Neural stem cell-derived exosomes in stroke models; oxidative stress assays |
| miR-20b-3p | Type I diabetic peripheral neuropathy | Plasma exosomes in diabetic rats; nerve conduction studies |
Cancer Progression and Immune Evasion
Exosomes can promote tumor growth, metastasis, and immune evasion by transferring oncogenic proteins and miRNAs. Negative regulation of exosomal secretion can inhibit these processes. For example, miR-144-3p promotes ferroptosis to inhibit osteosarcoma proliferation, migration, and invasion through regulating ZEB1. Prostate cancer cells secrete PD-1 in exosomes to enhance myeloid-derived suppressor cell activity and promote immune evasion, suggesting that blocking exosome secretion could restore anti-tumor immunity. Brucea javanica-derived exosome-like nanovesicles deliver miRNAs for cancer therapy, highlighting the therapeutic potential of modulating exosome secretion.
Neurodegenerative Diseases
Exosomes contribute to the spread of misfolded proteins in neurodegenerative diseases such as Alzheimer's and Parkinson's. Negative regulation of exosomal secretion may prevent disease progression. Exosomes derived from bone-marrow mesenchymal stem cells alleviate cognitive decline in AD-like mice by improving BDNF-related neuropathology. Human neural stem cell-derived exosomes activate PINK1/Parkin pathway to protect against oxidative stress-induced neuronal injury in ischemic stroke. Chaihu-Shugan-San alleviates post-stroke depression in mice via exosome-mediated neuroprotection.
Metabolic and Peripheral Neuropathies
Exosomes are involved in intercellular communication in metabolic disorders. Plasma exosomes improve peripheral neuropathy via miR-20b-3p/Stat3 in type I diabetic rats. This suggests that modulating exosome secretion could be a therapeutic strategy for diabetic complications.
From negative regulation of exosomal secretion-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does knockout of Rab27a reduce exosome secretion? | CRISPR knockout of Rab27a in HeLa or HEK293T cells; NTA and Western blot for exosome markers |
| Does a point mutation in ESCRT-III affect MVB formation? | CRISPR point mutation (e.g., in CHMP4B) followed by electron microscopy and exosome quantification |
| Can overexpression of a negative regulator inhibit exosome release? | Overexpression of miR-144-3p or Rab27a dominant-negative mutant; exosome secretion assays |
| What is the role of a candidate gene in exosome secretion? | CRISPR knockout or knockdown in cancer cell lines; RNA-seq and proteomics of exosomes |
| Does a specific miRNA target exosome secretion machinery? | Knock-in of miRNA target site mutations; luciferase reporter assays |
| Can pharmacological agents modulate exosome secretion? | Treatment of cells with inhibitors (e.g., GW4869) and measurement of exosome release |
How to Study the negative regulation of exosomal secretion Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Nanoparticle tracking analysis (NTA) | Size and concentration of exosomes | Quantify exosome release after knockout or treatment |
| Transmission electron microscopy (TEM) | Morphology of exosomes and MVBs | Validate exosome preparations and MVB ultrastructure |
| Western blot | Exosome marker proteins (CD63, CD81, TSG101) | Confirm exosome identity and quantify secretion |
| CRISPR knockout screens | Genes affecting exosome secretion | Identify negative regulators on a genome-wide scale |
| Live-cell imaging (TIRF) | MVB fusion events | Real-time assessment of fusion inhibition |
| Proteomics | Protein cargo of exosomes | Discover changes in exosome composition |
| RNA sequencing | miRNA and mRNA profiles | Identify regulatory RNAs and targets |
| Luciferase reporter assays | miRNA target validation | Confirm direct regulation of exosome-related genes |
Exosome Isolation and Characterization
Exosomes are typically isolated from conditioned media by differential ultracentrifugation, size-exclusion chromatography, or immunocapture. Characterization involves nanoparticle tracking analysis (NTA), transmission electron microscopy (TEM), and Western blotting for markers such as CD63, CD81, and TSG101. These methods are essential to quantify changes in exosome secretion upon genetic manipulation [1,5].
CRISPR-Based Genetic Screens
Genome-wide CRISPR knockout or activation screens can identify negative regulators of exosomal secretion. Cells are transduced with a CRISPR library, and exosome secretion is measured using a reporter system (e.g., CD63-GFP). Enriched sgRNAs reveal candidate genes whose loss increases or decreases exosome release. This approach has been used to uncover novel regulators of exosome biogenesis.
Live-Cell Imaging of MVB Fusion
Live-cell imaging using fluorescently tagged MVB markers (e.g., CD63-pHluorin) allows real-time visualization of MVB fusion with the plasma membrane. This technique can assess the effect of negative regulators on the final step of exosome secretion. It is often combined with total internal reflection fluorescence (TIRF) microscopy for high spatiotemporal resolution.
Proteomics and RNA Sequencing
Proteomic analysis of exosomes and cells can reveal changes in cargo composition upon modulation of negative regulators. RNA sequencing of exosomal RNA and cellular RNA can identify miRNAs and mRNAs affected by genetic perturbations. These omics approaches provide a systems-level view of exosome secretion regulation [6,8].
How CRISPR Can Be Used to Study GO:1903542 negative regulation of exosomal secretion
Knockout
CRISPR knockout is used to delete genes encoding negative regulators of exosomal secretion, such as Rab27a, Rab27b, or ESCRT components. This results in increased exosome release, confirming their inhibitory role. Knockout cell lines are generated by transfecting Cas9 and sgRNAs targeting the gene of interest, followed by single-cell cloning and validation by sequencing and Western blot.
Point Mutation
Point mutations can be introduced to dissect specific domains or residues required for negative regulation. For example, mutating the GTP-binding domain of Rab27a can create a dominant-negative mutant that inhibits exosome secretion. CRISPR-based base editing or homology-directed repair (HDR) with a donor template is used to introduce precise mutations.
Knock-in
Knock-in of reporter tags (e.g., GFP or luciferase) into endogenous loci allows real-time tracking of exosome secretion. For instance, knocking in CD63-GFP enables visualization of MVBs and exosome release. CRISPR knock-in is also used to introduce miRNA target site mutations to study regulation.
Overexpression
Overexpression of negative regulators, such as miR-144-3p or dominant-negative Rab27a, can suppress exosome secretion. This is achieved by lentiviral transduction or CRISPR activation (CRISPRa) to upregulate endogenous genes. Overexpression models are useful for gain-of-function studies [1,6].
How EDITGENE Supports negative regulation of exosomal secretion Research
Researchers studying negative regulation of exosomal secretion-related genes often need to determine whether a candidate gene is causally involved in the process. EDITGENE provides a comprehensive suite of CRISPR services to enable precise genetic manipulation and functional validation.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of exosomal secretion research.
Frequently Asked Questions About negative regulation of exosomal secretion
What is GO:1903542?
GO:1903542 is a Gene Ontology term for 'negative regulation of exosomal secretion', defined as any process that stops, prevents, or reduces the frequency, rate, or extent of exosomal secretion.
What genes are involved in negative regulation of exosomal secretion?
Key genes include Rab27a, Rab27b, ESCRT components, miR-144-3p, miR-149-3p, and PINK1/Parkin, among others [1,4,5,7].
How is exosomal secretion negatively regulated?
It can be regulated at multiple steps: MVB biogenesis, cargo sorting, and MVB fusion with the plasma membrane. Proteins like Rab GTPases and ESCRT components play critical roles [4,5].
Why is negative regulation of exosomal secretion important in cancer?
It can inhibit the transfer of oncogenic signals and immune evasion molecules, thereby suppressing tumor progression [1,5].
What experimental models are used to study negative regulation of exosomal secretion?
Common models include CRISPR knockout of regulatory genes, overexpression of inhibitory proteins, and live-cell imaging of MVB fusion [1,5,7].
How can I measure exosome secretion?
Exosome secretion is typically measured by nanoparticle tracking analysis, Western blot for exosome markers, and live-cell imaging [1,5].
What is the role of Rab27a in exosome secretion?
Rab27a regulates MVB docking and fusion with the plasma membrane; its inhibition reduces exosome release.
Can microRNAs regulate exosomal secretion?
Yes, microRNAs such as miR-144-3p and miR-149-3p can modulate exosome secretion by targeting mRNAs of regulatory proteins [1,4].
What diseases are associated with dysregulated exosomal secretion?
Cancer, neurodegenerative diseases, and metabolic disorders such as diabetic neuropathy [1,2,6].
How can CRISPR help study negative regulation of exosomal secretion?
CRISPR allows precise knockout, knock-in, or point mutation of candidate genes to determine their causal role in exosome secretion [5,7].
Conclusion
Negative regulation of exosomal secretion (GO:1903542) is a critical process that controls intercellular communication and is implicated in cancer, neurodegeneration, and metabolic diseases. Understanding the molecular players and mechanisms provides opportunities for therapeutic intervention. EDITGENE offers advanced CRISPR services to dissect these pathways and accelerate discovery.
References
- 1. Jiang M et al.. 2023. Exosome-mediated miR-144-3p promotes ferroptosis to inhibit osteosarcoma proliferation, migration, and invasion through regulating ZEB1.. Mol Cancer 22(1):113 PMID: 37461104
- 2. Liu S et al.. 2022. Exosomes derived from bone-marrow mesenchymal stem cells alleviate cognitive decline in AD-like mice by improving BDNF-related neuropathology.. J Neuroinflammation 19(1):35 PMID: 35130907
- 3. Yan G et al.. 2024. Brucea javanica derived exosome-like nanovesicles deliver miRNAs for cancer therapy.. J Control Release 367:425-440 PMID: 38295998
- 4. Cao Y et al.. 2021. Enterotoxigenic Bacteroidesfragilis Promotes Intestinal Inflammation and Malignancy by Inhibiting Exosome-Packaged miR-149-3p.. Gastroenterology 161(5):1552-1566.e12 PMID: 34371001
- 5. Zhang J et al.. 2025. Prostate Cancer Cells Secrete PD-1 in Exosomes to Enhance Myeloid-Derived Suppressor Cell Activity and Promote Tumor Immune Evasion.. Cancer Res 85(18):3435-3453 PMID: 40698651
- 6. Li J et al.. 2023. Plasma exosomes improve peripheral neuropathy via miR-20b-3p/Stat3 in type I diabetic rats.. J Nanobiotechnology 21(1):447 PMID: 38001489
- 7. Zhao M et al.. 2025. Human neural stem cell-derived exosomes activate PINK1/Parkin pathway to protect against oxidative stress-induced neuronal injury in ischemic stroke.. J Transl Med 23(1):402 PMID: 40188077
- 8. Wu Q et al.. 2025. Chaihu-Shugan-San alleviates post-stroke depression in mice: Mechanistic insights into exosome-mediated neuroprotection.. J Ethnopharmacol 347:119700 PMID: 40154896
